Jeff Aronin: Supporting Breakthroughs In Biomedical Science For 20 Years

Experienced bioscience entrepreneur Jeff Aronin wants to help the sick and suffering by supporting the creation of the medicines they need. For over 20 years he has been doing just that. After earning a bachelor’s degree from Northern Illinois University and graduating from DePaul University with an MBA, Aronin worked in the healthcare industry for a short while. Then in 2000 he decided to begin making his dream of producing drugs to treat rare and neglected diseases a reality. He founded Ovation Pharmaceuticals. The company focused on developing the drugs patients desperately needed.


Ovation Pharmaceuticals was a huge success. In 2009, Jeff Aronin sold the company to Dutch healthcare concern Lundbeck for $900 million. During the 10 month transition period, Aronin was Lundbeck’s CEO and president to help ensure the company would maintain its upward trajectory. Then in 2010, Jeff Aronin became president and CEO of Paragon Biosciences. The Chicago based company is a business incubator designed to help innovative biotech companies get the resources they need to recruit world-class talent and get the support they require to bring new medications to market.


Under the leadership of Jeff Aronin, Paragon Biosciences has been a leading investor in over 200 new biomedical companies focused on novel science. One of the companies that have benefitted from the work of Aronin and Paragon Biosciences is Castle Creek Pharmaceuticals, which develops medications for rare genetic dermatology conditions. Harmony Biosciences, which creates treatments for narcolepsy, cataplexy and other central nervous system disorders, is another of those companies that Paragon Biosciences is helping turn novel ideas into solutions for suffering patients.


Jeff Aronin supports a number of organizations in the Chicago community. He’s on the directorial boards of World Business Chicago and Discover Financial Services. Aronin is also actively involved with the Museum of Science and Industry, ChicagoNEXT and several other local groups. Aronin and Paragon Biosciences also participate in public/private partnerships designed to create employment opportunities in the biosciences, stimulate interest in and support for innovation by youth and people in underserved communities. Jeff Aronin is committed to improving the quality of people’s lives.


The Thought Processes Of Jorge Moll Have Enabled Him To Become A Successful Entrepreneur

Jorge Moll received his education in Rio de Janeiro at the Federal University. In 1994 he earned his medical degree. This was followed by the completion of his residency in neurology in 1998. In 2004 he earned his experimental pathophysiology degree. He is currently the President, senior researchers and board member of IDOR or the D’Or Institute of Research and Education. Dr. Jorge Moll was honored by Stanford University when he received the Visiting Scholar Award. In 2012 he was elected as a board member for the International Neuroethics Society. In 2008 the Brazilian Academy of Sciences elected him as an affiliate member. He attended the National Institutes of Health from 2004 until 2007 where he earned his Research Fellow accolade.


Dr. Jorge Moll believes people waste too much time acting on an idea. He feels this may deprive people of something that may benefit them. He stated an idea should be either discarded or implemented. He developed IDOR because he wanted to promote new innovations in healthcare. This passion turned into an idea that shaped his life. Meetings have become an important part of him remaining productive. This is when he discusses ideas and research. Dr. Jorge Moll has meetings with students, entrepreneurs, staff members, distinguished researchers, numerous organizations, scientists and business associates. He feels these meeting represent collaboration and free expression.


Dr. Jorge Moll believes the most difficult dilemma regarding ideas is choosing the ones most likely to achieve success. These ideas are discussed, dropped or an action plan is formed by him team. What intrigues him are artificial intelligence and cognitive systems. He finds watching the way machines and human brains work together with the purpose of improving healthcare exciting. He is also interested in regenerative medicine and gene therapy. Dr. Jorge Moll has become successful as an entrepreneur due to his openness, transparency and nimbleness. He believes innovative science has been stifled by publication and career pathways. He feels these challenges can be combated with new models so the higher risk projects can be accomplished easier. He feels new models are necessary to prevent people from continually performing the same actions.